(Pr)ELIDEL® (pimecrolimus) cream Now Reimbursed Under Alberta's Public Drug Plan for Eligible Patients with Mild to Moderate Atopic Dermatitis

RegulatoryapprovedELIDELPositive

AI Analysis

Summary

ELIDEL (pimecrolimus) cream has been added to Alberta's Public Drug Plan reimbursement list for eligible patients with mild to moderate atopic dermatitis, expanding patient access in Canada.

Outcome Details

Reimbursement coverage under Alberta's Public Drug Plan for eligible patients with mild to moderate atopic dermatitis

Importance:4/10

Sentiment:

0.60

ReimbursementCanadaDermatologyPublic Drug Plan

Related Companies

$BHC

Read the original article

Published by yahoo_finance on July 28, 2026 12:00 PM

Read Original